Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Thibaut du Fayet | Chief Executive Officer | 355.47k | -- | 1968 |
| Dr. Jérôme Bailly Pharm.D. | Deputy CEO, Deputy GM, Chief Quality Officer & Qualified Person | 257.79k | -- | 1979 |
| Mr. Frédéric Mathat | Chief Financial Officer | -- | -- | -- |
| Ms. Cindy Fevre | Chief Scientific Officer | -- | -- | -- |
| Naomi Eichenbaum | Director Investor Relations | -- | -- | -- |
| Dr. Pascal Birman M.D. | Chief Medical Officer | -- | -- | -- |
| Dr. Philip L. Lorenzi M.D., Ph.D. | Consultant & Member of Scientific Board | -- | -- | -- |
| Prof. Eric Raymond M.D., Ph.D. | Consultant & Member of Scientific Board | -- | -- | -- |
| Dr. Bridget Bax Ph.D. | Consultant & Member of Scientific Board | -- | -- | -- |
| Prof. Arthur E. Frankel M.D., Ph.D. | Consultant & Member of Scientific Board | -- | -- | -- |
PHAXIAM Therapeutics S.A.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 68
Description
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.
Corporate Governance
Upcoming Events
March 13, 2025 at 3:00 PM UTC
PHAXIAM Therapeutics S.A. Earnings Date
Recent Events
Recent Events Information Not Available